The Fertility Gap No One Is Talking About

‍

Infertility affects millions of women around the world, upwards of 8 million in the US. Yet, it remains one of the most under-discussed and underserved challenges in healthcare, shaping not only physical health, but emotional well-being, financial stability, and the ability to build a family on one’s own terms.

Infertility is no longer something happening quietly in the background—it is a global reality, touching millions of women and reshaping how families are built. And for the first time, we are seeing real momentum toward change.

Why Now — and Why This Matters to Investors

That change doesn’t happen on its own. It happens when capital flows into overlooked problems, when innovation meets lived experience, and when investors recognize both the urgency and the opportunity.

Despite this global impact, fertility sits within a $50B+ market inside a $600B+ women’s health sector that has historically been overlooked by investors, leaving enormous unmet need and untapped opportunity. 

Portfolia is stepping into that gap. 

We are actively reshaping the fertility landscape, problems that matter to you, by investing in solutions that address one of the most overlooked and fastest-growing markets in healthcare: women’s infertility.

 Despite fertility representing a $50B+ global market within a $600B+ women’s health sector, it has historically received only a fraction of venture funding, leaving massive unmet need and opportunity on the table.

A New Generation of Fertility Companies

Across the fertility landscape, new companies are rethinking how care is delivered, experienced, and accessed—not just improving outcomes, but fundamentally redesigning the journey.

Maven: Connecting the Care Journey

Take Maven.

Maven is transforming fertility care by making it continuous, connected, and accessible. Through its digital platform, individuals can access a global network of providers spanning fertility, pregnancy, and family building. Instead of navigating a fragmented system alone, patients receive coordinated, personalized support throughout their journey.

By working with employers and health plans, Maven is also expanding access—bringing fertility care to people who might otherwise never receive it.

Proov: Putting Women in Control of Their Own Data

At the same time, companies like Proov are changing how people understand their own fertility.

Proov puts critical hormone insights directly into women’s hands through at-home testing. Instead of waiting for clinical intervention, individuals can track ovulation, monitor hormone health, and take action earlier. That shift—from reactive to proactive—can significantly improve outcomes while reducing cost and stress.

Gameto: Reimagining IVF from the Ground Up

Then there is Gameto, working at the frontier of what fertility treatment itself can become.

Gameto is a clinical-stage biotechnology company reimagining IVF from the inside out. Its lead program, Fertilo, uses engineered stem cells to mature eggs outside the body. This potentially replaces the weeks of intensive hormonal injections that make traditional IVF so physically and emotionally demanding. The goal is an IVF process that is shorter, safer, and more accessible, without sacrificing outcomes. With Phase 3 trials underway in the U.S. and clearance already granted in markets like Australia and Latin America, Gameto is not just improving fertility care;it is rebuilding one of its most fundamental procedures from the ground up.

Investing in the Future of Fertility

Together, these companies represent a broader shift: fertility care that is more accessible, more informed, and more patient-centered.

At Portfolia, that belief is core to how we invest. By backing companies that are expanding access, improving outcomes, and putting women at the center of care, we are helping turn infertility from an underserved challenge into a space of real progress.

Because when you invest in solving problems that matter deeply, the impact extends far beyond returns—it changes lives, families, and the future of healthcare itself.